prednisolone has been researched along with Malignant Carcinoid Syndrome in 3 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Malignant Carcinoid Syndrome: A symptom complex associated with CARCINOID TUMOR and characterized by attacks of severe flushing of the skin, diarrheal watery stools, bronchoconstriction, sudden drops in blood pressure, edema, and ascites. The carcinoid tumors are usually located in the gastrointestinal tract and metastasize to the liver. Symptoms are caused by tumor secretion of serotonin, prostaglandins, and other biologically active substances. Cardiac manifestations constitute CARCINOID HEART DISEASE. (Dorland, 27th ed; Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dose escalation was required in order to control carcinoid symptoms, and the final dosage was 5,950 micrograms/day." | 1.29 | Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide. ( Deguchi, H; Deguchi, K; Iwasaki, E; Kobayashi, T; Murashima, S; Shirakawa, S; Tsuda, M; Tsukada, T, 1994) |
| "Prednisolone, which was initially effective, was replaced by SMS201-995 due to the considerable dose increase of the former because its effect became insufficient during the course of the treatment." | 1.27 | Successful treatment with a long-acting somatostatin analogue (SMS201-995) in a patient with malignant carcinoid syndrome. ( Deguchi, K; Iwasaki, E; Murashima, S; Shirakawa, S; Tamaki, S; Tsuda, M, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deguchi, H | 1 |
| Deguchi, K | 2 |
| Tsukada, T | 1 |
| Murashima, S | 2 |
| Iwasaki, E | 2 |
| Tsuda, M | 2 |
| Kobayashi, T | 1 |
| Shirakawa, S | 2 |
| Tamaki, S | 1 |
| Turck, WP | 1 |
| Grant, IW | 1 |
| Zeitlin, IJ | 1 |
| Smith, AN | 1 |
3 other studies available for prednisolone and Malignant Carcinoid Syndrome
| Article | Year |
|---|---|
Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoid Tumor; Combined Modal | 1994 |
Successful treatment with a long-acting somatostatin analogue (SMS201-995) in a patient with malignant carcinoid syndrome.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Delayed-Action Preparations; Humans; Liver Neoplasms; Lung | 1988 |
Airways obstruction in the carcinoid syndrome. A study of the effect of drugs and other factors. II. Investigation of reversible airways obstruction.
Topics: Airway Obstruction; Aprotinin; Atropine; Dietary Proteins; Eating; Epinephrine; Histamine Release; H | 1972 |